New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

[1]  M. Stratton,et al.  Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Noelle,et al.  B7 family checkpoint regulators in immune regulation and disease. , 2013, Trends in immunology.

[3]  Z. Yao,et al.  Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. , 2013, Cancer letters.

[4]  Robert F. Schwabe,et al.  The microbiome and cancer , 2013, Nature Reviews Cancer.

[5]  S. Lowe,et al.  p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells , 2013, The Journal of experimental medicine.

[6]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[7]  G. Dranoff.  Immunotherapy at Large: Balancing tumor immunity and inflammatory pathology , 2013, Nature Medicine.

[8]  M. Smyth,et al.  Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors , 2013, Proceedings of the National Academy of Sciences.

[9]  F. Marincola,et al.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. , 2013, Immunity.

[10]  C. Horak,et al.  Nivolumab plus ipilimumab in advanced melanoma. , 2013, The New England journal of medicine.

[11]  I. Weissman,et al.  Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies , 2013, Science.

[12]  Bart Spiessens,et al.  Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Gilson,et al.  TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells , 2013, Nature Cell Biology.

[14]  Michael R. Green,et al.  Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. , 2013, The Journal of clinical investigation.

[15]  Jimmy Lin,et al.  Mining Exomic Sequencing Data to Identify Mutated Antigens Recognized by Adoptively Transferred Tumor-reactive T cells , 2013, Nature Medicine.

[16]  J. Galon,et al.  From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. , 2013, Current opinion in immunology.

[17]  W. Chng,et al.  ATM-dependent spontaneous regression of early Eμ-myc-induced murine B-cell leukemia depends on natural killer and T cells. , 2013, Blood.

[18]  L. Zender,et al.  T-helper-1-cell cytokines drive cancer into senescence , 2013, Nature.

[19]  C. Datz,et al.  Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth , 2012, Nature.

[20]  Ming Li,et al.  An Immunosurveillance Mechanism Controls Cancer Cell Ploidy , 2012, Science.

[21]  R. Schreiber,et al.  Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state. , 2012, Cancer research.

[22]  S. Gasser,et al.  Ras Activation Induces Expression of Raet1 Family NK Receptor Ligands , 2012, The Journal of Immunology.

[23]  D. Olive,et al.  B and T Lymphocyte Attenuator Mediates Inhibition of Tumor-Reactive CD8+ T Cells in Patients After Allogeneic Stem Cell Transplantation , 2012, The Journal of Immunology.

[24]  Rui-Ru Ji,et al.  An immune-active tumor microenvironment favors clinical response to ipilimumab , 2012, Cancer Immunology, Immunotherapy.

[25]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[26]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[27]  M. Smyth,et al.  CD73: a potent suppressor of antitumor immune responses. , 2012, Trends in immunology.

[28]  Stefan Michiels,et al.  Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Schreiber,et al.  Abstract 526: Cancer immunoediting by the innate immune system in the absence of adaptive immunity , 2012 .

[30]  Jens-Peter Volkmer,et al.  The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors , 2012, Proceedings of the National Academy of Sciences.

[31]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[32]  G. Dranoff,et al.  Combining immunotherapy and targeted therapies in cancer treatment , 2012, Nature Reviews Cancer.

[33]  J. Castle,et al.  Exploiting the mutanome for tumor vaccination. , 2012, Cancer research.

[34]  Ornella Pagliano,et al.  CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. , 2012, Cancer research.

[35]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[36]  George Coukos,et al.  Cancer immunotherapy comes of age , 2011, Nature.

[37]  T. Jacks,et al.  Expression of tumour-specific antigens underlies cancer immunoediting , 2011, Nature.

[38]  T. Luedde,et al.  Senescence surveillance of pre-malignant hepatocytes limits liver cancer development , 2011, Nature.

[39]  F. Marincola,et al.  Molecular Insights on the Peripheral and Intratumoral Effects of Systemic High-Dose rIL-2 (Aldesleukin) Administration for the Treatment of Metastatic Melanoma , 2011, Clinical Cancer Research.

[40]  K. Murphy,et al.  Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8α+ dendritic cells , 2011, The Journal of experimental medicine.

[41]  R. Schreiber,et al.  Type I interferon is selectively required by dendritic cells for immune rejection of tumors , 2011, The Journal of experimental medicine.

[42]  Axel Benner,et al.  Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. , 2011, Cancer research.

[43]  Eric C. Sorenson,et al.  Imatinib potentiates anti-tumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido , 2011, Nature Medicine.

[44]  L. Old,et al.  Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™ , 2011, Cancer Immunology, Immunotherapy.

[45]  Jan Tavernier,et al.  Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors , 2011, Nature Medicine.

[46]  Yan Zheng,et al.  Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment. , 2011, Current opinion in immunology.

[47]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[48]  R. Schreiber,et al.  Natural innate and adaptive immunity to cancer. , 2011, Annual review of immunology.

[49]  David C. Gondek,et al.  VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses , 2011, The Journal of experimental medicine.

[50]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[51]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[52]  T. Jacks,et al.  Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. , 2011, Cancer cell.

[53]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[54]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.

[55]  Z. Trajanoski,et al.  Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer. , 2010, Gastroenterology.

[56]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[57]  M. Schwaiger,et al.  TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis. , 2008, Cancer cell.

[58]  Lloyd J. Old,et al.  Adaptive immunity maintains occult cancer in an equilibrium state , 2007, Nature.

[59]  Robert D. Schreiber,et al.  Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.

[60]  Eric J. Brown,et al.  The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor , 2005, Nature.

[61]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[62]  R. Schreiber,et al.  IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity , 2001, Nature.

[63]  M. Burnet.  Cancer—A Biological Approach , 1957, British medical journal.

[64]  H. Moch,et al.  NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. , 2013, Cancer immunity.

[65]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.